Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2017

01.06.2017 | Clinical trial

Identifying long-term survivors among metastatic breast cancer patients undergoing primary tumor surgery

verfasst von: Tae-Kyung Yoo, Byung Joo Chae, Sei Joong Kim, JungSun Lee, Tae In Yoon, Soo Jung Lee, Ho Yong Park, Heung Kyu Park, Yong Hwa Eom, Hyung Suk Kim, Chang Jong Kim, Man sik Shin, Sun Hyong You, Byung Joo Song

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The prognostic role of primary tumor surgery in women with metastatic breast cancer at diagnosis is contentious. A subset of patients who will benefit from aggressive local treatment is needed to be identified. Using a nationwide database, we developed and validated a predictive model to identify long-term survivors among patients who had undergone primary tumor surgery.

Methods

A total of 150,043 patients were enrolled in the Korean Breast Cancer Registry between January 1990 and December 2014. Of these, 2332 (1.6%) presented with distant metastasis at diagnosis. Using Cox proportional hazards regression, we developed and validated a model that predicts survival in patients who undergo primary tumor surgery, based on the clinicopathological features of the primary tumor.

Results

A total of 2232 metastatic breast cancer patients were reviewed. Of these, 1541 (69.0%) patients had undergone primary tumor surgery. The 3-year survival rate was 62.6% in this subgroup. Among these patients, advanced T-stage, high-grade tumor, lymphovascular invasion, negative estrogen receptor status, high Ki-67 expression, and abnormal CA 15-3 and alkaline phosphatase levels were associated with poor survival. A prediction model was developed based on these factors, which successfully identified patients with remarkable survival (score 0–3, 3-year survival rate 87.3%). The clinical significance of the model was also validated with an independent dataset.

Conclusions

We have developed a predictive model to identify long-term survivors among women who undergo primary tumor surgery. This model will provide guidance to patients and physicians when considering surgery as a treatment modality for metastatic breast cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat National Comprehensive Cancer Network (NCCN) (2016) Clinical practice guidelines in oncology: breast cancer. http://www.nccn.org website. Accessed 31 Aug 2016 National Comprehensive Cancer Network (NCCN) (2016) Clinical practice guidelines in oncology: breast cancer. http://​www.​nccn.​org website. Accessed 31 Aug 2016
3.
Zurück zum Zitat Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA (2007) Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988–2003 SEER data. Ann Surg Oncol 14(8):2187–2194. doi:10.1245/s10434-007-9438-0 CrossRefPubMed Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA (2007) Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988–2003 SEER data. Ann Surg Oncol 14(8):2187–2194. doi:10.​1245/​s10434-007-9438-0 CrossRefPubMed
10.
12.
Zurück zum Zitat Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S (2004) Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 64(6):2205–2211CrossRefPubMed Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S (2004) Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 64(6):2205–2211CrossRefPubMed
15.
16.
Zurück zum Zitat Shien T, Nakamura K, Shibata T et al (2012) A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017. Jpn J Clin Oncol 42(10):970–973. doi:10.1093/jjco/hys120 CrossRefPubMed Shien T, Nakamura K, Shibata T et al (2012) A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017. Jpn J Clin Oncol 42(10):970–973. doi:10.​1093/​jjco/​hys120 CrossRefPubMed
17.
Zurück zum Zitat Soran A, Ozmen V, Ozbas S et al (2013) Abstract S2–03: early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer; Turkish study (protocol MF07-01). Cancer Res 73(24 Supplement):S2–03. doi:10.1158/0008-5472.sabcs13-s2-03 CrossRef Soran A, Ozmen V, Ozbas S et al (2013) Abstract S2–03: early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer; Turkish study (protocol MF07-01). Cancer Res 73(24 Supplement):S2–03. doi:10.​1158/​0008-5472.​sabcs13-s2-03 CrossRef
18.
Zurück zum Zitat Mittendorf EA (2010) Early surgery or standard palliative therapy in treating patients with stage IV breast cancer (ECOG 2108). NCT01242800 Mittendorf EA (2010) Early surgery or standard palliative therapy in treating patients with stage IV breast cancer (ECOG 2108). NCT01242800
19.
Zurück zum Zitat Soran A, Ozbas S, Karanlik H et al (2016) A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). J Clin Oncol 34:suppl; abstr 1005 Soran A, Ozbas S, Karanlik H et al (2016) A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). J Clin Oncol 34:suppl; abstr 1005
21.
Zurück zum Zitat Moon HG, Han W, Noh DY (2010) Comparable survival between pN0 breast cancer patients undergoing sentinel node biopsy and extensive axillary dissection: a report from the Korean Breast Cancer Society. J Clin Oncol 28(10):1692–1699. doi:10.1200/jco.2009.25.9226 CrossRefPubMed Moon HG, Han W, Noh DY (2010) Comparable survival between pN0 breast cancer patients undergoing sentinel node biopsy and extensive axillary dissection: a report from the Korean Breast Cancer Society. J Clin Oncol 28(10):1692–1699. doi:10.​1200/​jco.​2009.​25.​9226 CrossRefPubMed
25.
Zurück zum Zitat Pathy NB, Verkooijen HM, Taib NA, Hartman M, Yip CH (2011) Impact of breast surgery on survival in women presenting with metastatic breast cancer. Br J Surg 98(11):1566–1572. doi:10.1002/bjs.7650 CrossRefPubMed Pathy NB, Verkooijen HM, Taib NA, Hartman M, Yip CH (2011) Impact of breast surgery on survival in women presenting with metastatic breast cancer. Br J Surg 98(11):1566–1572. doi:10.​1002/​bjs.​7650 CrossRefPubMed
27.
Zurück zum Zitat Harris E, Barry M, Kell MR (2013) Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann Surg Oncol 20(9):2828–2834. doi:10.1245/s10434-013-2998-2 CrossRefPubMed Harris E, Barry M, Kell MR (2013) Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann Surg Oncol 20(9):2828–2834. doi:10.​1245/​s10434-013-2998-2 CrossRefPubMed
29.
Zurück zum Zitat Finn RS, Crown JP, Lang I et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25–35. doi:10.1016/s1470-2045(14)71159-3 CrossRefPubMed Finn RS, Crown JP, Lang I et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25–35. doi:10.​1016/​s1470-2045(14)71159-3 CrossRefPubMed
30.
31.
Zurück zum Zitat Patrick J, Khan SA (2015) Surgical management of de novo stage IV breast cancer. J Natl Compr Cancer Netw 13(4):487–493 (quiz 493)CrossRef Patrick J, Khan SA (2015) Surgical management of de novo stage IV breast cancer. J Natl Compr Cancer Netw 13(4):487–493 (quiz 493)CrossRef
Metadaten
Titel
Identifying long-term survivors among metastatic breast cancer patients undergoing primary tumor surgery
verfasst von
Tae-Kyung Yoo
Byung Joo Chae
Sei Joong Kim
JungSun Lee
Tae In Yoon
Soo Jung Lee
Ho Yong Park
Heung Kyu Park
Yong Hwa Eom
Hyung Suk Kim
Chang Jong Kim
Man sik Shin
Sun Hyong You
Byung Joo Song
Publikationsdatum
01.06.2017
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4309-2

Weitere Artikel der Ausgabe 1/2017

Breast Cancer Research and Treatment 1/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.